VIAL
Compound comparison

CJC-1295 vs Tesamorelin

CJC-1295 and Tesamorelin are both peptide compounds evaluated on Vial: CJC-1295 is available as a compounded preparation with clinical-trial evidence, and Tesamorelin is available as a compounded preparation with clinical-trial evidence, offered by 16 and 3 verified providers respectively.

Vial summary · compiled from public records

At a glance

CJC-1295

Category
Peptide
FDA / legal status
Compoundable
Route
Subcutaneous
16providers on Vial →

Tesamorelin

Sold as Egrifta

Category
Peptide
FDA / legal status
Compoundable
Route
Subcutaneous
3providers on Vial →

Side by side

FieldCJC-1295Tesamorelin
CategoryPeptidePeptide
Brand namesEgrifta
FDA / legal statusCompoundableCompoundable
Evidence tierClinical TrialsClinical Trials
Administration routeSubcutaneousSubcutaneous
Compounding accessAvailable through 503A and 503B compounding pharmaciesAvailable through 503A and 503B compounding pharmacies
Providers on Vial16 listed3 listed
Typical price band$$ to $$$$$ to $$$

Verified providers offering each

Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.

85+ High Confidence70 to 84 Well Documented50 to 69 Limited ConfidenceUnder 50 Flagged

About each compound

About CJC-1295

A synthetic analog of growth hormone-releasing hormone (GHRH), this 30-amino acid peptide is modified with a drug affinity complex (DAC) that extends its half-life by binding to serum albumin. It stimulates pulsatile growth hormone secretion from the anterior pituitary by activating GHRH receptors. The compound has been investigated in clinical research for growth hormone deficiency and conditions associated with impaired GH/IGF-1 axis function.

About Tesamorelin

Tesamorelin is an FDA-approved GHRH analog indicated for HIV-associated lipodystrophy and is used off-label in optimization medicine for visceral fat reduction and cognitive enhancement. Clinical data shows significant reductions in visceral adipose tissue and emerging evidence suggests neuroprotective benefits in older adults. It produces stronger and more sustained GH elevation than sermorelin. Compounded versions are available through licensed pharmacies.

Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.

This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.

Related compound comparisons

Other comparisons in the same category.

All compound comparisons →